Morepen Laboratories posts record Q1 FY27 revenue and profit; EBITDA jumps 207%, PAT surges 394%; CDMO moves to full commercial scale
AI مارکیٹ کا خلاصہ
Morepen Laboratories reported record Q1'FY27 results with revenue up 34% YoY, EBITDA up 207% and PAT up 394%, alongside an 82.5bn INR CDMO order moving into full commercialization. The update signals stronger execution in contract manufacturing and API exports, but it is an idiosyncratic single-stock development with limited read-through to the broader listed universe and no direct linkage to crypto assets.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT+1.23%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
● Neutral
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
Morepen Laboratories reported its Q1 FY27 results for the quarter ended June 30, 2026, delivering its highest-ever quarterly performance. Revenue rose 34% year-on-year to Rs 575.31 crore, while net profit climbed 394% to Rs 56.35 crore. EBITDA stood at Rs 87.72 crore, up 207% from a year earlier, and the EBITDA margin expanded to 15.25% from 6.65%.
The company said its Rs 825 crore CDMO order has entered full-scale commercialization, with Rs 58 crore of commercial deliveries completed during the quarter. Management attributed the sharp improvement to meaningful progress in contract development and manufacturing as well as a stronger contribution from API exports.
